Form 4: ResMed CEO Michael Farrell Executes Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
ResMed's CEO, Michael J. Farrell, exercised stock options and sold shares of ResMed common stock under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On June 7, 2024, Michael J. Farrell, the CEO of ResMed Inc., exercised options to acquire 14,683 shares of ResMed common stock at a price of $84.98 per share.
- Simultaneously, Farrell sold 14,683 shares of ResMed common stock at a weighted average price of $211.6556, with individual sales prices ranging from $210.58 to $213.86.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on January 31, 2024.
- Following these transactions, Farrell directly owns 440,799 shares of ResMed common stock.
- Farrell also indirectly owns 4,090 shares through the Lisette and Michael Farrell Family Trust and an unspecified amount through the Lisette and Michael Farrell Foundation.
- The report also notes that Farrell purchased 46.9596 shares of ResMed stock on April 30, 2024, through the ResMed Employee Stock Purchase Plan.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by the CEO. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders. The use of a 10b5-1 plan suggests that these trades were pre-planned and not based on any inside information at the time of the transaction.
Comparison to Industry Standards
- Executive compensation packages often include stock options as a way to align management's interests with those of shareholders.
- Rule 10b5-1 plans are a common tool used by executives to sell shares in a compliant manner, avoiding accusations of insider trading.
- Comparing Farrell's holdings and trading activity to those of executives at similar companies like Philips or Fisher & Paykel Healthcare would provide further context.
Stakeholder Impact
- The stock sale could have a minor impact on the stock price, depending on market perception.
- The transactions provide transparency to shareholders regarding executive compensation and trading activity.
Key Dates
| Date | Description |
|---|---|
| 11/11/2018 | Date options first became exercisable. |
| 01/31/2024 | Date Rule 10b5-1 plan was adopted. |
| 04/30/2024 | Date of ResMed Employee Stock Purchase Plan transaction. |
| 06/07/2024 | Date of option exercise and stock sale. |
| 06/10/2024 | Date of signature on the Form 4. |
| 11/16/2024 | Expiration date of the options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.